{"filing":{"accession_number":"0001178913-26-003946","cik":"0001638097","ticker":"ENTX","company_name":"Entera Bio Ltd.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"zk2635891.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326003946/zk2635891.htm"},"events":[{"id":26102,"run_id":23702,"accession_number":"0001178913-26-003946","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Entera Bio disclosed financial results for the three months ended June 30, 2026, reporting a net loss of $7.3 million ($0.14 per share), cash position of $11.3 million, R\u0026D expenses of $3.2 million, and G\u0026A expenses of $1.4 million.","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27114,"accession_number":"0001178913-26-003946","item_number":"2.02","item_title":"Results of Operations and Financial","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Entera Bio's financial results for the three months ended June 30, 2026, including cash position ($11.3 million), R\u0026D expenses ($3.2 million), G\u0026A expenses ($1.4 million), and net loss ($7.3 million or $0.14 per share). This is a standard quarterly earnings release issued via press release on August 7, 2026, and furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the canonical Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:06:24.131507+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27115,"accession_number":"0001178913-26-003946","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses Entera's second quarter 2026 financial results, including cash position ($11.3M as of June 30, 2026), R\u0026D expenses ($3.2M), G\u0026A expenses ($1.4M), and net loss ($7.3M or $0.14 per share). The press release in Exhibit 99.1 is a standard earnings announcement with quarterly financial metrics and business updates, which is the hallmark of an earnings_release disclosure under Item 2.02 (incorporated by reference into Item 7.01).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:06:24.131507+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27114,"accession_number":"0001178913-26-003946","item_number":"2.02","item_title":"Results of Operations and Financial","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Entera Bio's financial results for the three months ended June 30, 2026, including cash position ($11.3 million), R\u0026D expenses ($3.2 million), G\u0026A expenses ($1.4 million), and net loss ($7.3 million or $0.14 per share). This is a standard quarterly earnings release issued via press release on August 7, 2026, and furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the canonical Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:06:24.131507+00:00","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-08-07"},{"id":27115,"accession_number":"0001178913-26-003946","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses Entera's second quarter 2026 financial results, including cash position ($11.3M as of June 30, 2026), R\u0026D expenses ($3.2M), G\u0026A expenses ($1.4M), and net loss ($7.3M or $0.14 per share). The press release in Exhibit 99.1 is a standard earnings announcement with quarterly financial metrics and business updates, which is the hallmark of an earnings_release disclosure under Item 2.02 (incorporated by reference into Item 7.01).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:06:24.131507+00:00","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-08-07"}]}